ERBB2 and neoplasm: As Herceptin has antitumour activity in only one out of three of the patients, it is ineffective on ErbB2-low-expressing tumour cells, and patients often develop resistance to the drug after about one year of treatment, the attention has been directed towards alternative strategies, such as the use of combinatorial therapeutic protocols.